New drug combo shows promise for Tough-to-Treat uterine cancer
NCT ID NCT03016338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cells repair themselves, while TSR-042 boosts the immune system to attack cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- niraparib and dostarlimab (TSR-042)
- What this could lead to
- If successful, this could offer a new treatment option to control recurrent endometrial cancer, potentially slowing tumor growth.
- What could go wrong
- This is an early-phase trial with only 51 participants, so results may not apply to all patients. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, K7L 5P9, Canada
-
Juravinski Cancer Centre
Hamilton, Ontario, L8V 5C2, Canada
-
London Regional Cancer Centre
London, Ontario, N6A 4L6, Canada
-
McGill University Health Centre - Glen Site
Montreal, Quebec, H3A 3J1, Canada
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1M9, Canada
-
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?